Show Notes
For people waiting for a lung transplant, every phone call could be life changing. But too many donor lungs are still turned down. In this episode of Tomorrow’s Cure from Mayo Clinic, host Cathy Wurzer explores how ex vivo lung perfusion, or EVLP, is helping turn a “no” into a “maybe” and sometimes a “yes” for patients who are running out of options.
Cathy talks with Mayo Clinic cardiothoracic surgeon Dr. Jack Haney and Brandi Zofkie, Associate Vice President at Lung Bioengineering, about how EVLP keeps lungs alive outside the body so experts can better evaluate and sometimes improve them before transplant. They discuss real patient impact, the logistics of making this technology available to more centers and the honest challenges that still remain. Listeners will hear why this innovation matters now and what it could mean for the future of lung transplantation, from expanding the donor pool to offering more second chances to breathe.
How to listen and stay connected:• Subscribe to Tomorrow’s Cure on your favorite podcast app and follow the show so you never miss an episode.• Get the latest health information from Mayo Clinic’s experts—subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
Connect with Mayo Clinic:• Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/Follow • Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/Follow • Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinicFollow • Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.